These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 34053342)

  • 1. Psychedelics and health behaviour change.
    Teixeira PJ; Johnson MW; Timmermann C; Watts R; Erritzoe D; Douglass H; Kettner H; Carhart-Harris RL
    J Psychopharmacol; 2022 Jan; 36(1):12-19. PubMed ID: 34053342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.
    Johnson MW
    Curr Top Behav Neurosci; 2022; 56():213-227. PubMed ID: 35704271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts.
    Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW
    J Psychopharmacol; 2018 Jul; 32(7):756-769. PubMed ID: 29938565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat.
    Smigielski L; Kometer M; Scheidegger M; Krähenmann R; Huber T; Vollenweider FX
    Sci Rep; 2019 Oct; 9(1):14914. PubMed ID: 31649304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psilocybin: Good Trip or Bad Trip.
    Sellers EM
    Clin Pharmacol Ther; 2017 Oct; 102(4):580-584. PubMed ID: 28548221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.
    Carhart-Harris RL; Leech R; Erritzoe D; Williams TM; Stone JM; Evans J; Sharp DJ; Feilding A; Wise RG; Nutt DJ
    Schizophr Bull; 2013 Nov; 39(6):1343-51. PubMed ID: 23044373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
    Ross S
    Int Rev Psychiatry; 2018 Aug; 30(4):317-330. PubMed ID: 30102082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.
    Kuypers KP; Ng L; Erritzoe D; Knudsen GM; Nichols CD; Nichols DE; Pani L; Soula A; Nutt D
    J Psychopharmacol; 2019 Sep; 33(9):1039-1057. PubMed ID: 31303095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.
    Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D
    Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
    Davis AK; Barrett FS; May DG; Cosimano MP; Sepeda ND; Johnson MW; Finan PH; Griffiths RR
    JAMA Psychiatry; 2021 May; 78(5):481-489. PubMed ID: 33146667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin occasioned mystical-type experiences.
    James E; Robertshaw TL; Hoskins M; Sessa B
    Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.
    Rosenbaum D; Weissman C; Anderson T; Petranker R; Dinh-Williams LA; Hui K; Hapke E
    J Psychopharmacol; 2020 Jun; 34(6):612-622. PubMed ID: 32108529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.
    Burdick BV; Adinoff B
    Am J Drug Alcohol Abuse; 2013 Sep; 39(5):291-7. PubMed ID: 23968172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.